Experience with IO alone or in combination with chemotherapy (CT) is limited in transformed-ALK patients, and to date, there are no studies evaluating the role of CT and IO in patients with SCLC transformed from adenocarcinoma with ALK translocation. The gene discussed is ALK; the disease is small cell lung carcinoma.